Adalimumab Market Analysis - Forecast(2019 - 2024)

Report Code: HCR 0100 Report Format: PDF + Excel Database
Adalimumab, which is a patent product of the Abott Biotechnology Ltd., is a medication used for treatment of ulcerative colitis, psoriatic arthritis and rheumatoid arthritis. It also known as HUMIRA, intended to inject subcutaneously. Side effects of this product are vomiting, nausea, internal bleeding, psoriasis, anaphylaxis, respiratory tract infections, hepatitis B infection, liver injuries and headache etc. Invented by Jochen Salfeld, Adalimumab is accessible as a pre-filled, single use syringe. In December 2002, the U.S. FDA approved adalimumab for indications such as psoriatic arthritis, Crohn's disease, plaque psoriasis, ankylosing spondylitis, rheumatoid arthritis and ulcerative colitis etc.

Rising occurrence of arthritis is among the key drivers boosting the growth of the this market. The population of women is at a greater chance of arthritis because of huge loss of calcium from the body in comparison to the males. This is expected to fuel demand for adalimumab over the forecast period. Furthermore, the sedentary lifestyle of people across the globe aids in increasing arthritis prevalence. As per the Centre of Disease Prevention and Control, a large number of adults in U.S. have been found to have rheumatoid arthritis, arthritis, lupus, fibromyalgia and gout. However, increasing prices of adalimumab is among the key hindrance to the global market.

Adalimumab market is classified into applications as Rheumatoid Arthritis, Psoriasis, Crohn’s Disease, Ulcerative Colitis and Others. Further, the Global Adalimumab Market is bifurcated by regions into North America, Asia Pacific (APAC), Europe and Rest of the World. Presently, Europe and North America account for the largest market share in the global market. Factors that include advanced healthcare infrastructure and reimbursement coverage and availability of well-organized regulatory framework are the major drivers of the adalimumab market in Europe and North America market. Followed by which, Asia Pacific market is expected to witness a significant rise during the forecast period due to factors like rising disposable income, rapidly developing healthcare infrastructure and municipality/government measures to improve the healthcare sector. India and China amount as the highest population globally. Therefore, geriatric population across India and China is analyzed to grow in the near future as a result of which the adalimumab market is expected to witness a growth in the market. Abundance of geriatric population is further analyzed to bolster the anti-arthritis drugs demand.

Adalimumab Market

Some of the key players in the global Adalimumab market include:

  • AbbVie, Inc. (U.S.)
  • Amgen, Inc. (U.S.)
  • Pfizer, Inc. (U.S.)
  • Novartis AG(Switzerland)
  • Mylan N.V.(U.S.) among others.
1. Adalimumab Market - Overview
1.1. Definitions and Scope
2. Adalimumab Market - Executive summary
2.1. Market Revenue, Market Size and Key Trends by Company
2.2. Key Trends by type of Application
2.3. Key Trends segmented by Geography
3. Adalimumab Market 
3.1. Comparative analysis
3.1.1. Product Benchmarking - Top 10 companies
3.1.2. Top 5 Financials Analysis
3.1.3. Market Value split by Top 10 companies
3.1.4. Patent Analysis - Top 10 companies
3.1.5. Pricing Analysis 
4. Adalimumab Market – Startup companies Scenario Premium
4.1. Top 10 startup company Analysis by
4.1.1. Investment
4.1.2. Revenue
4.1.3. Market Shares
4.1.4. Market Size and Application Analysis
4.1.5. Venture Capital and Funding Scenario
5. Adalimumab Market – Industry Market Entry Scenario Premium
5.1. Regulatory Framework Overview
5.2. New Business and Ease of Doing business index
5.3. Case studies of successful ventures
5.4. Customer Analysis – Top 10 companies
6. Adalimumab Market Forces
6.1. Drivers
6.2. Constraints
6.3. Challenges
6.4. Porters five force model
6.4.1. Bargaining power of suppliers
6.4.2. Bargaining powers of customers
6.4.3. Threat of new entrants
6.4.4. Rivalry among existing players
6.4.5. Threat of substitutes 
7. Adalimumab Market -Strategic analysis
7.1. Value chain analysis
7.2. Opportunities analysis
7.3. Product life cycle
7.4. Suppliers and distributors Market Share
8. Adalimumab Market – By Applications (Market Size -$Million / $Billion)
8.1. Market Size and Market Share Analysis 
8.2. Application Revenue and Trend Research
8.3. Product Segment Analysis
8.3.1. Introduction
8.3.2. Rheumatoid Arthritis
8.3.3. Psoriasis
8.3.4. Chron’s Disease
8.3.5. Ulcerative Colitis and
8.3.6. Others
9. Adalimumab - By Geography (Market Size -$Million / $Billion)
9.1. Adalimumab Market - North America Segment Research
9.2. North America Market Research (Million / $Billion)
9.2.1. Segment type Size and Market Size Analysis 
9.2.2. Revenue and Trends
9.2.3. Application Revenue and Trends by type of Application
9.2.4. Company Revenue and Product Analysis
9.2.5. North America Product type and Application Market Size
9.2.5.1. U.S.
9.2.5.2. Canada 
9.2.5.3. Mexico 
9.2.5.4. Rest of North America
9.3. Adalimumab - South America Segment Research
9.4. South America Market Research (Market Size -$Million / $Billion)
9.4.1. Segment type Size and Market Size Analysis 
9.4.2. Revenue and Trends
9.4.3. Application Revenue and Trends by type of Application
9.4.4. Company Revenue and Product Analysis
9.4.5. South America Product type and Application Market Size
9.4.5.1. Brazil  
9.4.5.2. Venezuela
9.4.5.3. Argentina
9.4.5.4. Ecuador
9.4.5.5. Peru
9.4.5.6. Colombia 
9.4.5.7. Costa Rica
9.4.5.8. Rest of South America
9.5. Adalimumab - Europe Segment Research
9.6. Europe Market Research (Market Size -$Million / $Billion)
9.6.1. Segment type Size and Market Size Analysis 
9.6.2. Revenue and Trends
9.6.3. Application Revenue and Trends by type of Application
9.6.4. Company Revenue and Product Analysis
9.6.5. Europe Segment Product type and Application Market Size
9.6.5.1. U.K  
9.6.5.2. Germany 
9.6.5.3. Italy 
9.6.5.4. France
9.6.5.5. Netherlands
9.6.5.6. Belgium
9.6.5.7. Spain
9.6.5.8. Denmark
9.6.5.9. Rest of Europe
9.7. Adalimumab – APAC Segment Research
9.8. APAC Market Research (Market Size -$Million / $Billion)
9.8.1. Segment type Size and Market Size Analysis 
9.8.2. Revenue and Trends
9.8.3. Application Revenue and Trends by type of Application
9.8.4. Company Revenue and Product Analysis
9.8.5. APAC Segment – Product type and Application Market Size
9.8.5.1. China 
9.8.5.2. Australia
9.8.5.3. Japan 
9.8.5.4. South Korea
9.8.5.5. India
9.8.5.6. Taiwan
9.8.5.7. Malaysia
10. Adalimumab Market - Entropy
10.1. New product launches
10.2. M&A's, collaborations, JVs and partnerships
11. Adalimumab Market – Industry / Segment Competition landscape Premium
11.1. Market Share Analysis
11.1.1. Market Share by Country- Top companies
11.1.2. Market Share by Region- Top 10 companies
11.1.3. Market Share by type of Application – Top 10 companies
11.1.4. Market Share by type of Product / Product category- Top 10 companies
11.1.5. Market Share at global level- Top 10 companies
11.1.6. Best Practises for companies
12. Adalimumab Market – Key Company List by Country Premium
13. Adalimumab Market Company Analysis
13.1. Market Share, Company Revenue, Products, M&A, Developments
13.2. AbbVie, Inc
13.3. Amgen, Inc
13.4. Pfizer, Inc.
13.5. Novartis AG
13.6. Mylan N.V.
13.7. Boehringer Ingelheim GmbH and
13.8. Merck & Co
13.9. Company 8
13.10. Company 9
13.11. Company 10 and more
"*Financials would be provided on a best efforts basis for private companies"
14. Adalimumab Market -Appendix
14.1. Abbreviations
14.2. Sources
15. Adalimumab Market -Methodology Premium
15.1. Research Methodology
15.1.1. Company Expert Interviews
15.1.2. Industry Databases
15.1.3. Associations
15.1.4. Company News
15.1.5. Company Annual Reports
15.1.6. Application Trends
15.1.7. New Products and Product database
15.1.8. Company Transcripts
15.1.9. R&D Trends
15.1.10. Key Opinion Leaders Interviews
15.1.11. Supply and Demand Trends
List of Tables

Table 1: Adalimumab Market Overview 2019-2024
Table 2: Adalimumab Market Leader Analysis 2018-2019 (US$)
Table 3: Adalimumab Market Product Analysis 2018-2019 (US$)
Table 4: Adalimumab Market End User Analysis 2018-2019 (US$)
Table 5: Adalimumab Market Patent Analysis 2013-2018* (US$)
Table 6: Adalimumab Market Financial Analysis 2018-2019 (US$)
Table 7: Adalimumab Market Driver Analysis 2018-2019 (US$)
Table 8: Adalimumab Market Challenges Analysis 2018-2019 (US$)
Table 9: Adalimumab Market Constraint Analysis 2018-2019 (US$)
Table 10: Adalimumab Market Supplier Bargaining Power Analysis 2018-2019 (US$)
Table 11: Adalimumab Market Buyer Bargaining Power Analysis 2018-2019 (US$)
Table 12: Adalimumab Market Threat of Substitutes Analysis 2018-2019 (US$)
Table 13: Adalimumab Market Threat of New Entrants Analysis 2018-2019 (US$)
Table 14: Adalimumab Market Degree of Competition Analysis 2018-2019 (US$)
Table 15: Adalimumab Market Value Chain Analysis 2018-2019 (US$)
Table 16: Adalimumab Market Pricing Analysis 2019-2024 (US$)
Table 17: Adalimumab Market Opportunities Analysis 2019-2024 (US$)
Table 18: Adalimumab Market Product Life Cycle Analysis 2019-2024 (US$)
Table 19: Adalimumab Market Supplier Analysis 2018-2019 (US$)
Table 20: Adalimumab Market Distributor Analysis 2018-2019 (US$)
Table 21: Adalimumab Market Trend Analysis 2018-2019 (US$)
Table 22: Adalimumab Market Size 2018 (US$)
Table 23: Adalimumab Market Forecast Analysis 2019-2024 (US$)
Table 24: Adalimumab Market Sales Forecast Analysis 2019-2024 (Units)
Table 25: Adalimumab Market, Revenue & Volume,By Application, 2019-2024 ($)
Table 26: Adalimumab Market By Application, Revenue & Volume,By Rheumatoid Arthritis, 2019-2024 ($)
Table 27: Adalimumab Market By Application, Revenue & Volume,By Psoriasis, 2019-2024 ($)
Table 28: Adalimumab Market By Application, Revenue & Volume,By Chron’s Disease, 2019-2024 ($)
Table 29: Adalimumab Market By Application, Revenue & Volume,By Ulcerative Colitis, 2019-2024 ($)
Table 30: North America Adalimumab Market, Revenue & Volume,By Application, 2019-2024 ($)
Table 31: South america Adalimumab Market, Revenue & Volume,By Application, 2019-2024 ($)
Table 32: Europe Adalimumab Market, Revenue & Volume,By Application, 2019-2024 ($)
Table 33: APAC Adalimumab Market, Revenue & Volume,By Application, 2019-2024 ($)
Table 34: Middle East & Africa Adalimumab Market, Revenue & Volume,By Application, 2019-2024 ($)
Table 35: Russia Adalimumab Market, Revenue & Volume,By Application, 2019-2024 ($)
Table 36: Israel Adalimumab Market, Revenue & Volume,By Application, 2019-2024 ($)
Table 37: Top Companies 2018 (US$) Adalimumab Market, Revenue & Volume
Table 38: Product Launch 2018-2019 Adalimumab Market, Revenue & Volume
Table 39: Mergers & Acquistions 2018-2019 Adalimumab Market, Revenue & Volume


List of Figures
Figure 1: Overview of Adalimumab Market 2019-2024
Figure 2: Market Share Analysis for Adalimumab Market 2018 (US$)
Figure 3: Product Comparison in Adalimumab Market 2018-2019 (US$)
Figure 4: End User Profile for Adalimumab Market 2018-2019 (US$)
Figure 5: Patent Application and Grant in Adalimumab Market 2013-2018* (US$)
Figure 6: Top 5 Companies Financial Analysis in Adalimumab Market 2018-2019 (US$)
Figure 7: Market Entry Strategy in Adalimumab Market 2018-2019
Figure 8: Ecosystem Analysis in Adalimumab Market 2018
Figure 9: Average Selling Price in Adalimumab Market 2019-2024
Figure 10: Top Opportunites in Adalimumab Market 2018-2019
Figure 11: Market Life Cycle Analysis in Adalimumab Market
Figure 12: GlobalBy ApplicationAdalimumab Market Revenue, 2019-2024 ($)
Figure 13: Global Adalimumab Market - By Geography
Figure 14: Global Adalimumab Market Value & Volume, By Geography, 2019-2024 ($) 
Figure 15: Global Adalimumab Market CAGR, By Geography, 2019-2024 (%)
Figure 16: North America Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 17: US Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 18: US GDP and Population, 2018-2019 ($)
Figure 19: US GDP – Composition of 2018, By Sector of Origin
Figure 20: US Export and Import Value & Volume, 2018-2019 ($)
Figure 21: Canada Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 22: Canada GDP and Population, 2018-2019 ($)
Figure 23: Canada GDP – Composition of 2018, By Sector of Origin
Figure 24: Canada Export and Import Value & Volume, 2018-2019 ($)
Figure 25: Mexico Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 26: Mexico GDP and Population, 2018-2019 ($)
Figure 27: Mexico GDP – Composition of 2018, By Sector of Origin
Figure 28: Mexico Export and Import Value & Volume, 2018-2019 ($)
Figure 29: South America Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 30: Brazil Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 31: Brazil GDP and Population, 2018-2019 ($)
Figure 32: Brazil GDP – Composition of 2018, By Sector of Origin
Figure 33: Brazil Export and Import Value & Volume, 2018-2019 ($)
Figure 34: Venezuela Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 35: Venezuela GDP and Population, 2018-2019 ($)
Figure 36: Venezuela GDP – Composition of 2018, By Sector of Origin
Figure 37: Venezuela Export and Import Value & Volume, 2018-2019 ($)
Figure 38: Argentina Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 39: Argentina GDP and Population, 2018-2019 ($)
Figure 40: Argentina GDP – Composition of 2018, By Sector of Origin
Figure 41: Argentina Export and Import Value & Volume, 2018-2019 ($)
Figure 42: Ecuador Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 43: Ecuador GDP and Population, 2018-2019 ($)
Figure 44: Ecuador GDP – Composition of 2018, By Sector of Origin
Figure 45: Ecuador Export and Import Value & Volume, 2018-2019 ($)
Figure 46: Peru Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 47: Peru GDP and Population, 2018-2019 ($)
Figure 48: Peru GDP – Composition of 2018, By Sector of Origin
Figure 49: Peru Export and Import Value & Volume, 2018-2019 ($)
Figure 50: Colombia Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 51: Colombia GDP and Population, 2018-2019 ($)
Figure 52: Colombia GDP – Composition of 2018, By Sector of Origin
Figure 53: Colombia Export and Import Value & Volume, 2018-2019 ($)
Figure 54: Costa Rica Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 55: Costa Rica GDP and Population, 2018-2019 ($)
Figure 56: Costa Rica GDP – Composition of 2018, By Sector of Origin
Figure 57: Costa Rica Export and Import Value & Volume, 2018-2019 ($)
Figure 58: Europe Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 59: U.K Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 60: U.K GDP and Population, 2018-2019 ($)
Figure 61: U.K GDP – Composition of 2018, By Sector of Origin
Figure 62: U.K Export and Import Value & Volume, 2018-2019 ($)
Figure 63: Germany Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 64: Germany GDP and Population, 2018-2019 ($)
Figure 65: Germany GDP – Composition of 2018, By Sector of Origin
Figure 66: Germany Export and Import Value & Volume, 2018-2019 ($)
Figure 67: Italy Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 68: Italy GDP and Population, 2018-2019 ($)
Figure 69: Italy GDP – Composition of 2018, By Sector of Origin
Figure 70: Italy Export and Import Value & Volume, 2018-2019 ($)
Figure 71: France Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 72: France GDP and Population, 2018-2019 ($)
Figure 73: France GDP – Composition of 2018, By Sector of Origin
Figure 74: France Export and Import Value & Volume, 2018-2019 ($)
Figure 75: Netherlands Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 76: Netherlands GDP and Population, 2018-2019 ($)
Figure 77: Netherlands GDP – Composition of 2018, By Sector of Origin
Figure 78: Netherlands Export and Import Value & Volume, 2018-2019 ($)
Figure 79: Belgium Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 80: Belgium GDP and Population, 2018-2019 ($)
Figure 81: Belgium GDP – Composition of 2018, By Sector of Origin
Figure 82: Belgium Export and Import Value & Volume, 2018-2019 ($)
Figure 83: Spain Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 84: Spain GDP and Population, 2018-2019 ($)
Figure 85: Spain GDP – Composition of 2018, By Sector of Origin
Figure 86: Spain Export and Import Value & Volume, 2018-2019 ($)
Figure 87: Denmark Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 88: Denmark GDP and Population, 2018-2019 ($)
Figure 89: Denmark GDP – Composition of 2018, By Sector of Origin
Figure 90: Denmark Export and Import Value & Volume, 2018-2019 ($)
Figure 91: APAC Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 92: China Adalimumab Market Value & Volume, 2019-2024
Figure 93: China GDP and Population, 2018-2019 ($)
Figure 94: China GDP – Composition of 2018, By Sector of Origin
Figure 95: China Export and Import Value & Volume, 2018-2019 ($)Adalimumab Market China Export and Import Value & Volume, 2018-2019 ($)
Figure 96: Australia Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 97: Australia GDP and Population, 2018-2019 ($)
Figure 98: Australia GDP – Composition of 2018, By Sector of Origin
Figure 99: Australia Export and Import Value & Volume, 2018-2019 ($)
Figure 100: South Korea Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 101: South Korea GDP and Population, 2018-2019 ($)
Figure 102: South Korea GDP – Composition of 2018, By Sector of Origin
Figure 103: South Korea Export and Import Value & Volume, 2018-2019 ($)
Figure 104: India Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 105: India GDP and Population, 2018-2019 ($)
Figure 106: India GDP – Composition of 2018, By Sector of Origin
Figure 107: India Export and Import Value & Volume, 2018-2019 ($)
Figure 108: Taiwan Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 109: Taiwan GDP and Population, 2018-2019 ($)
Figure 110: Taiwan GDP – Composition of 2018, By Sector of Origin
Figure 111: Taiwan Export and Import Value & Volume, 2018-2019 ($)
Figure 112: Malaysia Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 113: Malaysia GDP and Population, 2018-2019 ($)
Figure 114: Malaysia GDP – Composition of 2018, By Sector of Origin
Figure 115: Malaysia Export and Import Value & Volume, 2018-2019 ($)
Figure 116: Hong Kong Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 117: Hong Kong GDP and Population, 2018-2019 ($)
Figure 118: Hong Kong GDP – Composition of 2018, By Sector of Origin
Figure 119: Hong Kong Export and Import Value & Volume, 2018-2019 ($)
Figure 120: Middle East & Africa Adalimumab Market Middle East & Africa 3D Printing Market Value & Volume, 2019-2024 ($)
Figure 121: Russia Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 122: Russia GDP and Population, 2018-2019 ($)
Figure 123: Russia GDP – Composition of 2018, By Sector of Origin
Figure 124: Russia Export and Import Value & Volume, 2018-2019 ($)
Figure 125: Israel Adalimumab Market Value & Volume, 2019-2024 ($)
Figure 126: Israel GDP and Population, 2018-2019 ($)
Figure 127: Israel GDP – Composition of 2018, By Sector of Origin
Figure 128: Israel Export and Import Value & Volume, 2018-2019 ($)
Figure 129: Entropy Share, By Strategies, 2018-2019* (%)Adalimumab Market 
Figure 130: Developments, 2018-2019*Adalimumab Market 
Figure 131: Company 1 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 132: Company 1 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 133: Company 1 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 134: Company 2 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 135: Company 2 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 136: Company 2 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 137: Company 3Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 138: Company 3Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 139: Company 3Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 140: Company 4 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 141: Company 4 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 142: Company 4 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 143: Company 5 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 144: Company 5 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 145: Company 5 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 146: Company 6 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 147: Company 6 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 148: Company 6 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 149: Company 7 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 150: Company 7 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 151: Company 7 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 152: Company 8 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 153: Company 8 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 154: Company 8 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 155: Company 9 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 156: Company 9 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 157: Company 9 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 158: Company 10 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 159: Company 10 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 160: Company 10 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 161: Company 11 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 162: Company 11 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 163: Company 11 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 164: Company 12 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 165: Company 12 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 166: Company 12 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 167: Company 13Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 168: Company 13Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 169: Company 13Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 170: Company 14 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 171: Company 14 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 172: Company 14 Adalimumab Market Net Sales Share, By Geography, 2018 (%)
Figure 173: Company 15 Adalimumab Market Net Revenue, By Years, 2018-2019* ($)
Figure 174: Company 15 Adalimumab Market Net Revenue Share, By Business segments, 2018 (%)
Figure 175: Company 15 Adalimumab Market Net Sales Share, By Geography, 2018 (%)